Clinical Trial Opportunities
Free Webinar: "Pancreatic Cancer Clinical Trials: What You Need to Know"
The Pancreatic Cancer Action Network hosts a panel discussion about clinical trials -- "Pancreatic Cancer Clinical Trials: What You Need to Know." Watch this excellent discussion for free by clicking here.
​
Clinical Trial: Early Detection for Pancreatic Cancer
ExoLuminate is a nationally enrolling registry study designed for earlier detection of cancer in those patients that are at an elevated risk or clinically suspicious for pancreatic ductal adenocarcinoma (PDAC).
For more information, click here.
​
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
In large a clinical trial, researchers in 15 U.S. hospitals, Germany, Japan, South Korea, and Spain are looking to evaluate immunotherapy-based treatment combinations in participants with metastasis pancreatic ductal adenocarcinoma (PDAC). The study is still recruiting and is estimated to be completed by June 2024.
Contact Information:
-
888-662-6728 (U.S. and Canada)
The National Familial Pancreas Tumor Registry (NFPTR)
NFPTR is a research registry at Johns Hopkins aimed at identifying the causes of pancreatic cancer, particularly pancreatic cancer that runs in families. The goal of their research is to improve the early detection and treatment of pancreatic cancer.
Data from the NFPTR has helped:
-
Demonstrate that individuals with a family history of pancreatic cancer are at an increased risk of developing pancreatic tumors.
-
Understand the genetic basis (both inherited and non-inherited) of pancreatic cancer.
-
Demonstrate that genes are an important cause of pancreatic cancer.
-
Develop tools to identify individuals at high risk of pancreatic cancer.
-
Show that pancreatic tumors can be detected early in high-risk individuals.
Click here for more information.
​
​
Precision Promise
​
Precision Promise is a large multi-center clinical trial sponsored by Pancreatic Cancer Action Network that is investigating several novel drug treatments for metastatic pancreatic cancer. The study will evaluate the following:
-
Active Comparator (i.e., a known effective treatment): Gemcitabine combined with nab-paclitaxel
-
Experimental: SM-88
-
Active Comparator: mFOLFIRINOX
-
Experimental: Pamrevlumab combined with gemcitabine and nab-paclitaxel
-
Experimental: Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
The study will measure overall survival time, progression free survival time, patient performance status, overall response rate (tumor size reduction), duration of overall response rate, and duration of clinical benefit.
​
Early Detection Initiative
EDI is a randomized controlled trial of an algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma (PDAC). It is a collaborative effort among Pancreatic Cancer Action Network, National Cancer Institute, and the Consortium for Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer. The study will be using the Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) which risk stratifies subjects into a very high-risk group, an intermediate risk group, and very-low risk for PDAC based on change in weight, change in blood glucose, and age at onset of diabetes. The researchers will also use a multi-detector pancreas-protocol computed tomography (MDCT) to screen for PDAC. The researchers hypothesize that these interventions in new-onset diabetes will identify earlier stage PDAC.
Click here for more on the Early Detection Initiative.
-
ClinicalTrials.gov Identifier: NCT04662879
Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
This clinical trial is investigating the safety and effectiveness of the addition of Eryaspase to FOLFIRINOX for the treatment of patients with advanced pancreatic cancer. In an interim update, the researchers suggest that the combination has generally been well tolerated. They plan to expand enrollment to further look at efficacy and are in the process of designing a larger randomized study.
ClinicalTrials.gov Identifier: NCT04292743
Contact: Marcus Noel, MD
202-444-2223
Marcus.S.Noel@gunet.georgetown.edu
District of Columbia
Georgetown Lombardi Comprehensive Cancer Center Recruiting
Washington, District of Columbia, 20007
Contact: Kerrie Bouker
202-687-0114
Principal Investigator: Marcus Noel, MD